Navigation Links
Sosei Announces Successful Completion of AD 923 Pharmacokinetic,Study in the USA

TOKYO, May 22, 2007 /PRNewswire-FirstCall/ -- Sosei Group Corporation , a biopharmaceutical company, today announces the successful completion of a study of its fentanyl sublingual spray (AD 923), an opioid analgesic for the treatment of cancer breakthrough pain.

This was a pharmacokinetic Phase I single centre, open-label, single dose, cross-over, randomised study of AD 923 versus Actiq(R) (oral transmucosal fentanyl citrate lozenge) and versus fentanyl citrate injection. The study was conducted in healthy human volunteers, under an IND in the United States. All of the primary and secondary objectives of the study were achieved.

The more rapid absorption of fentanyl from AD 923 compared with Actiq(R) was statistically significant, with substantial plasma exposure seen within 10 minutes. The median Tmax (time to maximum plasma concentration) for AD 923 was 40 minutes compared with 120 minutes for Actiq(R). In addition, the higher absolute bioavailability of AD 923 compared with Actiq(R) was also statistically significant. Both formulations were well tolerated with no significant safety issues identified.

Sosei has reached agreement with EU regulatory authorities to move AD 923 directly into Phase III trials and plan to file a CTA (clinical trial application) in the second half of 2007. Following the outcome of this pharmacokinetic study the company will continue its discussions with the FDA regarding the detailed requirements for the Phase III programme in the USA.

Mr Shinichi Tamura, President & CEO of Sosei, said: "These data demonstrate that AD 923 has the potential to provide significantly faster onset of analgesia compared with existing therapy. Additionally, the higher absolute bioavailability indicates more predictable pain relief across the patient population. These factors together with the ease of administration will provide an optimised product with a rapid onset of ac
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug ... treatment of Major Depressive Disorder in adult patients who have ... the current episode. TMS is a non-invasive technique for stimulating ... patients suffering from Major Depressive Disorder. The procedure has been ...
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Therapeutics,(OTC Bulletin Board: ECTE) today announced positive ... Transdermal Continuous Glucose Monitoring (tCGM),System in patients ... Echo,s non-invasive,Symphony tCGM System consists of its ... Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free skin ...
... TRIANGLE PARK, N.C., July 27 Timothy Mastro,MD, ... on August 1st,as Senior Director of Research, will ... for HIV prevention at the,International AIDS Conference in ... Prophylaxis: Current,and Planned Trials," will examine ongoing and ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2
(Date:8/29/2015)... ... 29, 2015 , ... Hamstring strain have not ... tissue manipulation. Platelet rich plasma injections also have mixed results. Building core ... treatment outcomes. This localized treatment seems to address the symptoms and does offer ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing number of ... transitioned management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published ... maker Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. LaRocco ... tends to take several months, but the current process, having already gone on for ...
(Date:8/28/2015)... ... 28, 2015 , ... As reported by Medical Daily on August 22 ... results that last for two years, the longest of any cellulite reduction system currently ... for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
Breaking Medicine News(10 mins):Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... older treatments may sometimes work best, researchers say , , ... the best therapy for irritable bowel syndrome (IBS) may ... peppermint oil, a new study finds. , According to ... because of the availability of newer (and more expensive) ...
... VIRGINIA BEACH, Va., Nov. 13, 2008 James G.,Carlson, Chairman ... statement on America,s "Premature Birth Report Card," which was,released November ... in America deserves a fair chance to grow up in ... clear with its ,Premature,Birth Report Card, that is not the ...
... WASHINGTON, Nov. 13 The U.S. government,through the ... of five planned shipments of U.S. emergency assistance ... 12. In coordination with the,UN Children,s Fund (UNICEF), ... blankets, 5,400 water containers, 500,rolls of plastic sheeting, ...
... this holiday ... season, FORT WORTH, Texas, ... partnering with St. Jude,during the 2008 holiday shopping season for the 5th anniversary ... and Giving campaign, RadioShack is asking customers to "Give thanks,for the healthy kids ...
... Acquisition of ... Haematology Business Assets, WAYNE, Pa., Nov. 13 Escalon ... first quarter ended,September 30, 2008., For the first quarter of ... $6,893,000 in fiscal 2007. This,included product revenue of $8,669,000 for the ...
... A new Web site designed to emphasize smoking prevention ... at Dartmouth (CHaD) and Dartmouth Medical School (DMS). The ... pediatrician Henry Bernstein to help prevent smoking in young ... through an unrestricted educational grant, the siteNo Smoking Room.Org ...
Cached Medicine News:Health News:Peppermint Oil, Fiber Can Fight Irritable Bowel 2Health News:Peppermint Oil, Fiber Can Fight Irritable Bowel 3Health News:AMERIGROUP Chairman and CEO Urges Action to Improve Nation's 'Premature Birth Report Card' 2Health News:First U.S. Flight with Humanitarian Goods Arrives in Democratic Republic of Congo 2Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 2Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 8Health News:Innovative new Web site empowers young girls to live smoke-free 2
Desmarres Infant Retractor...
Size 4 - 2.25 mm...
... the features of phaco systems costing much ... maintenance. Small, light and tough enough to ... cost reusable tubing kit can be auto-claved ... a price objection to purchasing a modern ...
Compact ultrasonic phacoemulsification system....
Medicine Products: